DESTINY-Endometrial01 phase 3 trial of Enhertu initiated as first-line therapy in patients with HER2 expressing primary ...
The first patient has been dosed in the DESTINYEndometrial01 phase 3 trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy (carboplatin and paclitaxel) in combination with …